Assessment of Allodynia Relief by Tissue-Protective Molecules in a Rat Model of Nerve Injury-Induced Neuropathic Pain - Tissue-Protective Cytokines: Methods and Protocols - page 189

Fig. 2 Effect of ARA290 on the development of neuropathic pain. Treatment with ARA290 results in the preven-
tion of developing: ( a ) tactile allodynia and ( b ) allodynia for cold for a period of 15 weeks

at least 15 weeks (Fig. 2a ). The allodynic responses differed
significantly between treatment groups (repeated measures
ANOVA, post hoc Holm-Sidak: P < 0.001 vs. vehicle-treated
animals).
Similarly, cold allodynia developed in animals treated with vehi-
cle following nerve lesion with mean scores between 3 and 4 (4 being
the maximum score) during the 15 week study period (Fig. 2b ).
Treatment with ARA290 was associated with significantly less cold
allodynia with mean scores between 1.8 and 2.9 (Kruskal-Wallis,
post hoc Tukey test: P < 0.001 vs. vehicle-treated animals).

4 Notes

1. Anesthesia is induced and maintained with vaporized anes-
thetic agents (i.e., sevoflurane, isoflurane) rather than ket-
amine, for ketamine and other NMDA receptor antagonists,
the class of drugs ketamine belongs to, have shown to reduce
neuropathic pain in both humans and animals ( 16, 17 ).
2. Literature describes this procedure to be done by making an
incision through the muscle ( 18 ). This induces collateral dam-
age and may cause blood loss. The method described in this
chapter has been developed to perform the procedure without
any to minimal blood loss.